Literature DB >> 17570959

Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.

Craig A Yury1, Jane E Fisher.   

Abstract

BACKGROUND: To review published reports of the usage of atypical antipsychotics for behavioural problems of dementia patients.
METHODS: The electronic database Medline was searched from 1999 to 2006 with a combination of search terms including 'behavioural problems' and 'atypical antipsychotics'.
RESULTS: Thirteen eligible studies were included in the overall analysis. The total number of participants was 1,683, of whom 1,015 received medication and 668 received placebo. Medications studied were risperidone, olanzapine, and quetiapine. Other studies examined other types of medications, such as typical versus atypical antipsychotics, but only data for atypical antipsychotics were included in the meta-analysis. The mean effect size for 7 placebo-controlled studies was 0.45 (95% CI = 0.16-0.74) for atypical antipsychotics, and 0.32 (95% CI = 0.10-0.53) for placebo. The mean effect size of all 13 studies included in the analysis was 0.31 (95% CI = 0.08-0.54).
CONCLUSIONS: In general, effect sizes of atypical antipsychotics for behavioural problems are medium, and there are no statistically or clinically significant differences between atypical antipsychotics and placebo. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570959     DOI: 10.1159/000101499

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  10 in total

1.  Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage.

Authors:  Mauro Giovanni Carta; Fausta Zairo; Gisa Mellino; Maria Carolina Hardoy
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-11-26

Review 2.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

3.  Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.

Authors:  Rajesh R Tampi; Deena J Tampi; Silpa Balachandran; Shilpa Srinivasan
Journal:  Ther Adv Chronic Dis       Date:  2016-07-15       Impact factor: 5.091

4.  Antipsychotics for agitation in dementia.

Authors:  Joey Ton; Jamil Ramji; G Michael Allan
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

5. 

Authors:  Joey Ton; Jamil Ramji; G Michael Allan
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

Review 6.  A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia.

Authors:  Maryse Lapeyre-Mestre
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

Review 7.  Managing Behavioral and Psychological Symptoms of Dementia (BPSD) in the Era of Boxed Warnings.

Authors:  Rajesh R Tampi; Gargi Bhattacharya; Padmapriya Marpuri
Journal:  Curr Psychiatry Rep       Date:  2022-07-04       Impact factor: 8.081

8.  Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing.

Authors:  Graham McIlroy; Sarah K Thomas; Jamie J Coleman
Journal:  J Public Health (Oxf)       Date:  2014-03-28       Impact factor: 2.341

Review 9.  Dealing with behavioral and psychological symptoms of dementia: a general overview.

Authors:  Majda Azermai
Journal:  Psychol Res Behav Manag       Date:  2015-07-03

Review 10.  Assessment and management of behavioral and psychological symptoms of dementia.

Authors:  Helen C Kales; Laura N Gitlin; Constantine G Lyketsos
Journal:  BMJ       Date:  2015-03-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.